Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol

2019772 citationsJournal Articlebronze Open Access

Authors

Kausik K. Ray · Imperial College London

Harold Bays · Louisville Metabolic and Atherosclerosis Research Center

Alberico L. Catapano · MultiMedica

Narendra D. Lalwani · Esperion Therapeutics (United States)

LeAnne T. Bloedon · Esperion Therapeutics (United States)

Lulu Ren Sterling · Esperion Therapeutics (United States)

Paula Robinson

Abstract

In this 52-week trial, bempedoic acid added to maximally tolerated statin therapy did not lead to a higher incidence of overall adverse events than placebo and led to significantly lower LDL cholesterol levels. (Funded by Esperion Therapeutics; CLEAR Harmony ClinicalTrials.gov number, NCT02666664.).

Topics & Keywords

Lipoproteins and Cardiovascular Health Cancer, Lipids, and Metabolism Aortic Thrombus and Embolism

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 380, Issue 11, pp. 1022-1032

DOI: 10.1056/nejmoa1803917

Field-Weighted Citation Impact: 86.70